Yousif Capital Management LLC Sells 1,060 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Yousif Capital Management LLC cut its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 6.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 16,668 shares of the company’s stock after selling 1,060 shares during the quarter. Yousif Capital Management LLC’s holdings in Amphastar Pharmaceuticals were worth $1,031,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Shaker Investments LLC OH boosted its holdings in shares of Amphastar Pharmaceuticals by 136.0% during the 4th quarter. Shaker Investments LLC OH now owns 49,078 shares of the company’s stock valued at $3,035,000 after buying an additional 28,283 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in Amphastar Pharmaceuticals by 44.8% during the third quarter. Jacobs Levy Equity Management Inc. now owns 554,850 shares of the company’s stock worth $25,518,000 after acquiring an additional 171,642 shares in the last quarter. Walleye Capital LLC purchased a new stake in shares of Amphastar Pharmaceuticals in the 3rd quarter worth approximately $1,833,000. Charles Schwab Investment Management Inc. increased its position in Amphastar Pharmaceuticals by 7.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 352,378 shares of the company’s stock valued at $16,206,000 after buying an additional 24,116 shares in the last quarter. Finally, Rafferty Asset Management LLC bought a new position in Amphastar Pharmaceuticals during the 3rd quarter valued at approximately $205,000. 65.09% of the stock is owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Stock Down 0.5 %

AMPH stock opened at $42.46 on Friday. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.17 and a quick ratio of 1.70. Amphastar Pharmaceuticals, Inc. has a 1-year low of $35.93 and a 1-year high of $67.66. The stock has a market capitalization of $2.04 billion, a P/E ratio of 16.46, a P/E/G ratio of 1.02 and a beta of 0.85. The business has a fifty day moving average price of $43.48 and a 200-day moving average price of $50.75.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its earnings results on Wednesday, February 28th. The company reported $0.81 earnings per share for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.03). The business had revenue of $178.11 million during the quarter, compared to analysts’ expectations of $174.90 million. Amphastar Pharmaceuticals had a return on equity of 26.95% and a net margin of 21.34%. Equities analysts forecast that Amphastar Pharmaceuticals, Inc. will post 3.41 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on AMPH. JPMorgan Chase & Co. started coverage on Amphastar Pharmaceuticals in a report on Tuesday, March 5th. They issued an “overweight” rating and a $60.00 target price on the stock. StockNews.com downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Finally, Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, April 10th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $66.00.

Insider Activity

In other news, Director Michael A. Zasloff sold 12,500 shares of the firm’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $47.18, for a total value of $589,750.00. Following the transaction, the director now directly owns 21,326 shares in the company, valued at approximately $1,006,160.68. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders have sold 14,000 shares of company stock valued at $655,145 in the last ninety days. 27.10% of the stock is currently owned by company insiders.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.